» Articles » PMID: 9296223

Carcinoid Tumors: Analysis of Prognostic Factors and Survival in 301 Patients from a Referral Center

Overview
Journal Ann Oncol
Publisher Elsevier
Specialty Oncology
Date 1997 Jul 1
PMID 9296223
Citations 118
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Little is known about factors related to prognosis in patients with carcinoid disease. In this study we have tried to identify such factors.

Patients And Methods: We have evaluated 301 consecutive carcinoid patients (256 midgut, 39 foregut and six hindgut) referred during 15 years for medical treatment with respect to tumor distribution, hormone production, prognostic factors and survival.

Results: Survival was significantly shorter in midgut carcinoid patients with > or = 5 liver metastases or with high levels of urinary 5-hydroxyindoleacetic acid, plasma chromogranin A or neuropeptide K. By univariate analysis, these variables together with the presence of carcinoid syndrome were related to a higher risk of dying. In multivariate analyses, performed in the 71 patients with full information on all variables, advanced age and plasma chromogranin A > 5000 micrograms/l were independent predictors of overall survival.

Conclusions: Poor prognostic factors for midgut carcinoid patients were multiple liver metastases, presence of carcinoid syndrome and high levels of the tumor markers studied. In this study the only independent predictors of bad prognosis in midgut, carcinoid patients were advanced age, which however is inherently related to overall survival, and plasma chromogranin A > 5000 micrograms/l. Thus, chromogranin A may prove to be an important prognostic marker for patients with carcinoid tumors.

Citing Articles

The Clinicopathological Characteristics and Surgical Treatment of Gastrointestinal Neuroendocrine Neoplasm-A 10-Year Single-Center Experience.

Serafin M, Jablonska B, Senderek E, Majewska K, Mrowiec S J Clin Med. 2024; 13(16).

PMID: 39201037 PMC: 11355324. DOI: 10.3390/jcm13164892.


Biochemical Markers for Neuroendocrine Tumors: Traditional Circulating Markers and Recent Development-A Comprehensive Review.

Franchina M, Cavalcoli F, Falco O, La Milia M, Elvevi A, Massironi S Diagnostics (Basel). 2024; 14(12).

PMID: 38928704 PMC: 11203125. DOI: 10.3390/diagnostics14121289.


[Clinical significance of neuroendocrine tumors : Incidence, symptoms, diagnosis, stage, and prognostic factors and their influence on disease management].

Hartrampf P, Serfling S, Higuchi T, Bojunga J, Weich A, Werner R Radiologie (Heidelb). 2024; 64(7):536-545.

PMID: 38777918 DOI: 10.1007/s00117-024-01315-y.


Chemoembolization Beyond Hepatocellular Carcinoma: What Tumors Can We Treat and When?.

DePietro D, Li X, Shamimi-Noori S Semin Intervent Radiol. 2024; 41(1):27-47.

PMID: 38495263 PMC: 10940046. DOI: 10.1055/s-0043-1777716.


Hedinger Syndrome-Lessons Learnt: A Single-Center Experience.

El Gabry M, Arends S, Shehada S, Lahner H, Kamler M, Wendt D J Cardiovasc Dev Dis. 2023; 10(10).

PMID: 37887860 PMC: 10607344. DOI: 10.3390/jcdd10100413.